Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by SanFrancisco99on Jul 04, 2014 10:08am
231 Views
Post# 22715834

RE:Phase III will be a formality

RE:Phase III will be a formalityAgreed Sir!

I think the focus is now very much on the future.  That's great, finally.  One more hurdle and I think shareholders reach the City of Gold finally on this one.

I have heard talk of the next trial possibly being cut short if the results are strong.  Wouldn't it be amazing if we got an update on the results at 6 months - and found that the results mirrored Sustain and Assure in terms of MACE?   A third trial showing the same thing would be very, very powerful evidence that we have a huge winner here.

So what's it worth if they show that???  That's the big question now.  I'm sure management has a very good idea from all the talks this year with big pharma and other interested parties about valuation.  I bet Dart knows exactly what the payoff will be....

I'm very curious to hear from management.  The next Webcast (whenever that is) will be very interesting.  Hopefully they can give us some idea of potential future valuation....  (although they might not to "go there" with us...)

If Re-Mace gives us the same Mace results and if they have solid autoimmune, metabolic and Azheimer's Data... what will the value of this formula be?  One billion?  Two billion?  More?

Even if only the MACE data is there, it's still worth a lot of money.  The other stuff/indications are icing.

Yes... the focus is again on the future.  And it is looking very bright once again.



Bullboard Posts